Format

Send to

Choose Destination
Sci Rep. 2018 Sep 25;8(1):14329. doi: 10.1038/s41598-018-32176-w.

GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals.

Author information

1
Institute of Bioscience, Language and Exact Science, UNESP - São Paulo State University, São José do Rio Preto, SP, Brazil.
2
Institute of Chemistry, UNESP - São Paulo State University, Araraquara, SP, Brazil.
3
Institute of Chemistry, UNESP - São Paulo State University, Araraquara, SP, Brazil. cilli@iq.unesp.br.
4
Institute of Bioscience, Language and Exact Science, UNESP - São Paulo State University, São José do Rio Preto, SP, Brazil. prahal@ibilce.unesp.br.

Abstract

In recent years, synthetic peptides have been considered promising targets for drug development that possess low side-effects, are cost-effective and are susceptible to rational design. Hecate was initially described as a potent bacterial inhibitor and subsequently as an anticancer drug with functions related to its lipid interaction property. Viruses, such as hepatitis C virus (HCV), have a lipid-dependent life cycle and could be affected by Hecate in many ways. Here, we assessed modifications on Hecate's N-terminus region and its effects on HCV and hepatotoxicity. Gallic acid-conjugated Hecate was the most efficient Hecate-derivative, presenting high potential as an antiviral and inhibiting between 50 to 99% of all major steps within the HCV infectious cycle. However, the most promising aspect was GA-Hecate's mechanism of action, which was associated with a balanced lipid interaction with the viral envelope and lipid droplets, as well as dsRNA intercalation, allowing for the possibility to affect other ssRNA viruses and those with a lipid-dependent cycle.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center